XML 29 R20.htm IDEA: XBRL DOCUMENT v3.6.0.2
Investment in Integumen and Secured Promissory Note (Details Narrative)
9 Months Ended
Jan. 31, 2017
USD ($)
$ / shares
Dec. 02, 2016
USD ($)
shares
Dec. 02, 2016
GBP (£)
shares
Jul. 12, 2016
USD ($)
Jul. 07, 2016
GBP (£)
May 28, 2016
Jan. 31, 2017
USD ($)
$ / shares
shares
Jan. 31, 2016
USD ($)
Jul. 07, 2016
USD ($)
Business combination consideration transferred             $ 2,696,105    
Assumption of certain liabilities             2,179,833    
Bank loan facility, description           Prior to a potential listing and fundraise, Integumen will fund its activities out of existing cash reserves and a bank loan facility for €1m which Venn Life Sciences      
Purchase consideration liabilities assumed $ 416,272           416,272    
Debt instrument face amount 100,000           100,000    
Gain on sale of assets             2,696,105    
Impairment loss recognized             $ (2,499)  
Investments $ 1           $ 1    
GBP [Member]                  
Business acquisition share price per share | $ / shares $ 0.65           $ 0.65    
Biosurface Limited [Member] | Option Agreement [Member]                  
Secured promissory note                 $ 100,000
Number of shares received by option $ 100,000                
Biosurface Limited [Member] | Option Agreement [Member] | Minimum [Member] | GBP [Member]                  
Exercise of option | £         £ 3,030,000        
Integumen Limited [Member]                  
Percentage of accrued interest rate   80.00% 80.00%            
Number of ordinary shares received | shares   2,632,868 2,632,868       2,179,833    
Business combination consideration transferred   $ 3,840,525              
Assumption of certain liabilities   416,272              
Prepayment of note   $ 100,000              
Percentage of accrued interest per annum 80.00%           80.00%    
Asset purchase agreement, description             The APA provided that 80 per cent of the Consideration Shares should be issued on completion of the APA and the remaining 20 per cent (subject to an adjustment depending on the value of the assumed liabilities) should be issued within 30 days of Admission of Integumen to AIM.    
Impairment loss recognized             $ 2,179,832    
Integumen Limited [Member] | GBP [Member]                  
Business acquisition share price per share | $ / shares $ 1           $ 1    
Business combination consideration transferred | £     £ 3,030,000            
Assumption of certain liabilities | £     320,209            
Prepayment of note | £     £ 76,923            
Integumen Limited [Member] | Option Agreement [Member]                  
Secured promissory note                 $ 100,000
Number of shares received by option       $ 100,000